ClinicalTrials.Veeva

Menu

Effects of Curcumin on Markers of Cardiovascular Risk in Patients With CAD

U

Universidade Federal Fluminense

Status

Withdrawn

Conditions

Coronary Artery Disease
Inflammation
Oxidative Stress

Treatments

Dietary Supplement: Curcumin

Study type

Interventional

Funder types

Other

Identifiers

NCT04458116
Denise Mafra9

Details and patient eligibility

About

  • General Objective To evaluate the effects of curcumin supplementation on cardiovascular risk markers, inflammation, oxidative stress and functional capacity in participants with coronary artery disease.

Specific Objectives

Assess, before and after supplementation with turmeric:

  • The nutritional status of the participants;
  • Blood pressure;
  • Atherogenic risk;
  • The expression of transcription factors (Nrf2 and NF-kB), antioxidant enzymes (NQO1, HO-1, sirtuin 1 (SIRT-1)), NLPR3 receptor, as well as the levels of inflammatory cytokines (IL-6, tumor necrosis factor-alpha (TNF-α), protein C reactive (PCR), IL-1, IL 18) and vascular cell adhesion protein 1 (VCAM-1) and E-selectin adhesion molecules;
  • Routine biochemical parameters;
  • Lipid peroxidation and oxidized LDL;
  • The 6-minute walk test, the recovery heart rate and the chair lift test;
  • Modifiable risk factors before and after supplementation;
  • The comparison of all parameters between groups.

Full description

Coronary Artery Disease (CAD) is the leading cause of death worldwide. CAD refers to the pathological process of atherosclerosis that affects the coronary arteries, often leading to obstruction by an atheromatous plaque. Oxidative stress is one of the most potent inducers of vascular inflammation in atherogenesis. Reactive oxygen species (ROS) regulate through nuclear factor kB (NF-kB), transcription factors and genes related to inflammation, thus, activation of NF-kB by ROS in the atherosclerosis patient is associated with vascular dysfunction and thus with inflammation and atherosclerosis. Recently, researchers have discovered a transcription factor identified as nuclear factor-erythroid 2-related factor 2 (Nrf2) transcription factor, which is responsible for the expression of antioxidant response element genes that can inhibit this pathway, thus providing cellular protection. Thus, several nutritional strategies have been studied, including the use of curcumin, a chemical compound of the class of curcumin produced by turmeric root (Curcuma longa). Turmeric is capable of promoting the activation of nuclear factor-erythroid 2-related factor 2 (Nrf2) transcription factor and inflammasome (NLPR3). These factors, in turn, are involved with the activity of nuclear factor kappa-B (NF-kB), a transcription factor that increases the synthesis of inflammatory cytokines. Thus, the present study aims to evaluate the effects of turmeric supplementation on cardiovascular risk markers, inflammation, oxidative stress and evaluation of functional capacity. Perspectives: This study aims to improve the inflammatory and oxidative stress status of patients with CAD with the use of turmeric, and thus try to reduce the risk factors related to the onset and progression of coronary artery disease.

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Non-smokers
  • with a previous diagnosis of coronary artery disease and / or altered myocardial scintigraphy, both performed by a cardiologist.

Exclusion criteria

  • autoimmune and infectious diseases
  • pregnant and lactating women
  • cancer
  • AIDS;
  • participants using catabolic drugs, antioxidant vitamin supplements and habitual intake of turmeric and turmeric.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

0 participants in 2 patient groups, including a placebo group

Tumeric Group
Experimental group
Description:
participants will receive capsules containing 1.5 grams of turmeric 95% curcumin
Treatment:
Dietary Supplement: Curcumin
Placebo Group.
Placebo Comparator group
Description:
will receive capsules containing corn starch.
Treatment:
Dietary Supplement: Curcumin

Trial contacts and locations

1

Loading...

Central trial contact

Denise Mafra, PhD; Ludmila Cardozo, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems